Theralase® to Present at ThinkEquity Conference

TMX Newsfile | Oct 9, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – October 9, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical-stage pharmaceutical company dedicated to the research and development of proprietary Energy-Activated Small Molecules (“EASMs“) for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company has been invited to present at the 2026 ThinkEquity Conference in New York. ThinkEquity is a boutique investment bank that has collectively financed over $50 billion of public and private capital raises, restructurings, mergers and acquisitions. The annual ThinkEquity Conference brings together institutional investors, accredited investors and industry executives with private and public emerging growth companies, featuring corporate presentations across numerous sectors. The 2026 ThinkEquity Conference is expected to feature 85 company presentations, more than 750 attendees and more than 750 one-on-one investor meetings. Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., … Read More

Correcting and Replacing: Theralase®Releases Q2 2026 Financial Statements

TMX Newsfile | Sep 18, 2026 7:00 AM EDT Theralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline This Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg) Toronto, Ontario–(Newsfile Corp. – September 18, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released its unaudited interim consolidated financial statements for the six-month period ended June 30th, 2026 (“Financial Statements“). Theralase® will be hosting a conference call on September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for the quarter ended June 30th, 2026. To ensure Theralase® has time to address questions during the call, please e-mail them in advance to mperraton@theralase.com. Zoom Meeting Link: … Read More

Theralase® Commences GLP Toxicology Analysis of Rutherrin®

TMX Newsfile | Sep 15, 2026 7:00 AM EDT Successful completion of GLP toxicology analysis for the intravenous administration of Rutherrin(R) lays the groundwork for regulatory submissions supporting first-in-human clinical development for multiple life-threatening cancers Toronto, Ontario–(Newsfile Corp. – September 15, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Good Laboratory Practice (“GLP“) toxicology analysis of intravenously administered Rutherrin® has commenced. Rutherrin® is formed by combining Theralase®’s lead small molecule Ruvidar® with transferrin (blood plasma protein made by the liver that transports iron throughout the body). Rutherrin® has demonstrated preclinically the ability to target cancer cells and after energy-activation destroy the target cancer cell. The GLP toxicology analysis of Rutherrin® represents an important step … Read More

Theralase® Releases Q2 2026 Financial Statements

TMX Newsfile | Aug 28, 2026 4:36 PM EDT Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline Toronto, Ontario–(Newsfile Corp. – August 28, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released the Company’s unaudited interim consolidated financial statements for the six-month period ended June 30th, 2026 (“Financial Statements“). Theralase® will be hosting a conference call on September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for the quarter ended June 30th, 2026. To ensure Theralase® has time to address questions during the call, please e-mail them in advance to mperraton@theralase.com. Zoom Meeting Link: https://us02web.zoom.us/j/89698954744      Conference Call in:  Webinar ID: 896 9895 4744 – … Read More

Theralase® Closes C$3.6 Million Brokered Financing

TMX Newsfile | Aug 24, 2026 5:01 PM EDT Toronto, Ontario–(Newsfile Corp. – August 24, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering (“Offering“), pursuant to which the Company issued 14,812,500 units (“Units“) at a price of C$0.24 per Unit (“Offering Price“) for aggregate gross proceeds of C$3,555,000. The Offering was led by Research Capital Corporation as sole agent and sole bookrunner (“Agent“) Each Unit consists of one common share of the Company (“Common Share“) and one Common Share purchase warrant (“Warrant“). Each Warrant entitles the holder thereof to purchase one Common Share (“Warrant Share“) at an exercise price of C$0.32 per Warrant Share at any … Read More

Theralase®Announces $5 Million Brokered LIFE Offering

TMX Newsfile | Aug 10, 2026 5:15 PM EDT Toronto, Ontario–(Newsfile Corp. – August 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation (“RCC” or the “Agent“) to act as the sole agent and sole bookrunner on a commercially reasonable “best efforts” agency basis for a brokered private placement offering (“Offering“) of units of the Company (“Units“) at a price of C$0.24 per Unit, to raise a minimum of C$3,000,000 and up to a maximum of C$5,000,000.16 in aggregate gross proceeds. Each Unit will consist of one common share of the Company (“Common Share“) and one Common Share purchase warrant (“Warrant“). Each Warrant shall entitle the … Read More

Theralase® Grants Stock Options

TMX Newsfile | Aug 7, 2026 5:25 PM EDT Toronto, Ontario–(Newsfile Corp. – August 7, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options. The Company has granted an aggregate of 7,000,000 stock options to eligible participants pursuant to the Company’s stock option plan. The options are exercisable at a price of C$0.265 per common share, vest over a three-year period and expire five years from the date of grant. The stock option grant is subject to acceptance by the TSX Venture Exchange. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses. Additional … Read More

Theralase® Engages Global One Media to Expand Global Investor Awareness

TMX Newsfile | Aug 4, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – August 4, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has engaged Global One Media Group Pte. Ltd. (“Global One Media“) to provide digital investor marketing and communications services to the Company. Global One Media is an arm’s-length investor marketing firm headquartered in Singapore that specializes in digital investor communications for publicly traded companies. Its services include strategic messaging, video production, social media communications and international distribution across investor-focused media channels. Commencing August 1, 2026, Global One Media will assist Theralase® with an investor awareness program designed to increase the Company’s visibility and communicate its corporate, scientific and clinical developments to investors … Read More

Theralase® Receives Receipt for C$100 Million Base Shelf Prospectus

TMX Newsfile | Jun 30, 2026 4:30 PM EDT Toronto, Ontario–(Newsfile Corp. – June 30, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 (“Prospectus“) with the securities regulatory authorities in all provinces and territories of Canada. The Prospectus will allow Theralase® to offer up to C$100 Million of common shares, warrants, subscription receipts, debt securities or any combination thereof (collectively, the “Securities“), over a 25-month period. Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase®, stated, “The approval of the Prospectus represents an important milestone for the Company, providing up to C$100 Million of capital, if … Read More

Theralase® Lists Warrants on the TSXV

TMX Newsfile | Jun 3, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – June 3, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that the TSX Venture Exchange (“TSXV“) has accepted for listing up to 20,399,050 common share purchase warrants of the Company (“Warrants“), bearing the CUSIP: 88337V142, for trading on the TSXV. The Warrants are expected to commence trading on the TSXV at the open of markets on June 9th, 2026, under the trading symbol “TLT.WT“. The Warrants were issued pursuant to a brokered private placement (“Private Placement“) of the Company that closed on May 20th, 2026, in which the Company issued: The Private Placement raised aggregate gross proceeds of C$4,600,000 and included the full exercise … Read More